Back to search results

REGN7508 for Blood Clots in People with Cancer

This study is looking at a drug called REGN7508 to treat and prevent blood clots (venous thromboembolism or VTE) in adults. VTE includes deep vein thrombosis (DVT), which are blood clots in deep veins, and pulmonary embolism (PE), which are blood clots in the lungs. The study has two parts: one for people with or without cancer who have DVT, and another for people with cancer who have DVT or PE. Researchers want to see how safe and effective REGN7508 is compared to another treatment called apixaban. They will measure side effects and how long it takes for new blood clots to form. You may be able to join if you are 18 or older, have a cancer diagnosis (unless it's only basal-cell or squamous-cell skin cancer), and meet certain health criteria.

Study design
This is an interventional study planning to enroll 1600 participants. It compares REGN7508 to apixaban.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for side effects for approximately 6 months and for new blood clots for up to approximately 3.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07493304

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Recruiting
PHASE3Ages 18+InterventionalTreatment
Regeneron Pharmaceuticals
~1,600 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:REGN7508Apixaban

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Measured over Approximately 6 months
+3 more outcomes measured

Conditions

Venous Thromboembolism (VTE)

Explore related trials

Deep Vein ThrombosisHematologic NeoplasmPulmonary EmbolismSolid NeoplasmVenous Thromboembolism

Where it's being run

6 sites across 6 states
Florida1
New York1
Texas1
Gyeonggi-do1
Gyeongsangnam-do1
South Korea1

Study leadership

  • Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals

Who to contact

Clinical Trials Administrator
[email protected]
844-734-6643
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Occurrence of Treatment-Emergent Adverse Events (TEAEs)Approximately 6 months

    Part 1

  • Severity of TEAEsApproximately 6 months

    Part 1

  • Time-to-first event of centrally adjudicated recurrent VTE [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery] )or VTE-related death)]Up to approximately 3.5 years

    Part 2

  • Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleedingUp to approximately 3.5 years

    Part 2